What Avetabiomics does

Aveta Biomics is a privately held, clinical-stage biotechnology company headquartered in Bedford, Massachusetts, founded in 2014 to develop first-in-class oral immunomodulatory cancer therapies based on its proprietary Orthologous Molecular Structures (OMS) platform. The OMS platform leverages evolutionary biology insights to design rational combinations of botanical molecules that are structurally and functionally similar to human endogenous metabolites, enabling multi-agent, multi-targeting drugs intended to address tumor molecular heterogeneity and prevent the evolution of drug resistance. The company's lead asset, APG-157, is an oral immunotherapy in a registrational Phase 3 trial for head and neck squamous cell carcinoma (HNSCC) — both as neoadjuvant therapy for resectable patients and induction/maintenance for unresectable patients — and is being evaluated across 50+ global clinical centers. APG-157 received FDA Fast Track Designation in August 2024 and is differentiated by a PD-L1-independent mechanism that targets both immunologically "hot" and "cold" tumors, with no Grade ≥3 treatment-related adverse events observed in Phase 2 trials to date.

The company has an early-stage pipeline beyond HNSCC: AMAX126 is a preclinical candidate for Diffuse Intrinsic Pontine Glioma (DIPG), and the platform is being explored in high-grade adult gliomas where Bevacizumab monotherapy is the current standard with poor outcomes. Aveta is pre-revenue and generates no product sales today; its distribution model for the investigational drug consists of a global clinical trial network and an FDA-compliant Expanded Access Program, with commercialization economics expected to flow through out-licensing or partnership upon regulatory approval. The company is led by CEO and co-founder Parag G. Mehta, PhD, alongside a C-suite drawn from Iovance Biotherapeutics, Sanofi, Genzyme, Agios Pharmaceuticals, and Servier, and a board featuring former Bristol-Myers Squibb CEO Peter R. Dolan, former SEC Chief Economist S.P. Kothari, and senior McKinsey healthcare partners. Scientific advisors include Harvard Professors Eugene Shakhnovich and Daniel Hartl.

Name

Avetabiomics

Legal name

Aveta Biomics, Inc.

Website

https://avetabiomics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Aveta Biomics is a pre-revenue clinical-stage biotech developing first-in-class oral immunotherapies based on its Orthologous Molecular Structures (OMS) evolutionary biology platform; lead asset APG-157 is in a registrational Phase 3 trial for head and neck cancer with FDA Fast Track Designation.

Ownership category

akta.pro rank

Product category

Clinical-stage oncology drug development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Immunotherapy drug development
• Oncology clinical trials
• Oral cancer therapeutics
• Evolutionary biology platform
• Head and neck cancer

Headquarters

HQ city

Bedford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing first-in-class oral immunomodulatory therapies for cancer treatment. Revenue will be generated through drug commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Aveta Biomics is a clinical-stage biotechnology company developing first-in-class oral immunomodulatory therapies for cancer treatment using its proprietary Orthologous Molecular Structures (OMS) platform. The platform leverages evolutionary biology to design multi-agent, multi-targeting drugs that address tumor molecular heterogeneity and prevent the evolution of drug-resistant cancers. Lead candidate APG-157 is in a registrational Phase 3 trial as neoadjuvant therapy for head and neck squamous cell carcinoma (HNSCC), working independently of PD-L1 status across both immunologically 'hot' and 'cold' tumors.

Product overview

Avetabiomics is a clinical-stage biotechnology company developing a new class of oral immunomodulatory therapies based on its Orthologous Molecular Structures (OMS) Platform. The company's lead product is APG-157, an oral immunotherapy in a registrational Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). APG-157 works independently of PD-L1 status, making it effective across both 'hot' and 'cold' tumors. The company also has AMAX126 in preclinical development for pediatric DIPG brain cancer, and is conducting preclinical studies in high-grade adult glioma. Their approach uses evolution-inspired combination therapeutics derived from botanical molecules that are structurally and functionally similar to human endogenous metabolites.

Differentiator

Problem solved

Functional benefit

Products and services

• APG-157 First-in-class oral immunomodulatory immunotherapy candidate designed to reprogram the tumor microenvironment. Works independently of PD-L1 status to target both 'hot' and 'cold' tumors by inducing selective apoptosis of cancer cells while simultaneously reprogramming the immune environment to prevent recurrence through arrest of cancer stem cells. Administered orally with topical application and systemic absorption through the oral cavity. Lead indication is head and neck squamous cell carcinoma (HNSCC).
• AMAX126 Novel mechanism drug candidate for Diffuse Intrinsic Pontine Glioma (DIPG), a highly aggressive pediatric brain tumor typically diagnosed in children aged 5 to 10 with median survival of less than one year. In preclinical development with early evidence of efficacy.
• Orthologous Molecular Structures (OMS) Platform Drug discovery platform based on insights into evolutionary biology that designs rational combinations of multifunctional botanical molecules called Orthologous Metabolite Structures (OMS). The platform addresses molecular heterogeneity of tumors and prevents evolution of drug-resistant cancers through evolutionary synergy among molecules and pleiotropic modulation of targets.

Quantifiable outcome

• Phase 2A trial demonstrated encouraging signals in event-free survival, disease control, ctDNA clearance, and tumor reduction
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• VA Greater Los Angeles Healthcare System (VAGLAHS)coreStrategic or Co-development Partner · 9 April 2026Research collaboration with researchers from VA Greater Los Angeles Healthcare System for clinical investigation of APG-157 in head and neck squamous cell carcinoma. Joint presentation of Phase 2A subpopulation data at AACR 2026 demonstrating HPV viral load reduction and anti-tumor immunity activation.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Merck & Co. Developer of Keytruda (pembrolizumab), the dominant PD-1 inhibitor approved as standard of care in HNSCC. Direct competitive incumbent in Aveta's lead indication, though operating across a vastly broader oncology portfolio.
• Bristol-Myers Squibb: Developer of Opdivo (nivolumab), approved for HNSCC and other cancers. Major immuno-oncology incumbent and notable because Aveta board member Peter Dolan is former CEO/Chairman of BMS.

Direct peers

• Replimune: Clinical-stage biotech developing oncolytic immunotherapies for solid tumors including HNSCC. Comparable as a clinical-stage immuno-oncology company pursuing novel mechanisms in HNSCC; Aveta's CMO previously worked at Replimune.
• Innate Pharma: Clinical-stage immuno-oncology company developing innate immune system modulators (monoclonal antibodies, ADCs) for cancer treatment. Comparable as a clinical-stage biotech pursuing novel immunomodulatory mechanisms in oncology.
• Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunomodulators for solid tumors. Comparable clinical-stage immuno-oncology profile; Aveta's CBO previously served as CBO at Pyxis Oncology.
• Regeneron Pharmaceuticals: Developer of Libtayo (cemiplimab), a PD-1 inhibitor approved in HNSCC. Direct competitor in the same indication; Aveta's SVP Regulatory previously held senior roles at Regeneron.
• Marker Therapeutics: Clinical-stage biotech developing MultiTAA-specific T cell therapies for HNSCC and other solid tumors. Comparable as a clinical-stage immuno-oncology company pursuing novel mechanisms in HNSCC.
• Cue Biopharma: Clinical-stage biotech developing Immuno-STAT biologics that selectively modulate T cells for cancer, including HNSCC. Directly comparable as a clinical-stage immuno-oncology company with novel immunomodulatory approach.
• Iovance Biotherapeutics: Clinical-stage cell therapy biotech for solid tumors. Comparable as a clinical-stage oncology biotech with novel immunomodulatory mechanism; Aveta's CMO previously led clinical sciences at Iovance.
• Kura Oncology: Clinical-stage oncology biotech developing tipifarnib for HRAS-mutant HNSCC. Direct peer in HNSCC drug development with similar stage and indication focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aveta-biomics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avetabiomics